The health and medical applications of biotechnology are heavily influenced by technological development and demographic shifts. Australians are often early adopters of new health technology, driving demand and giving Australian companies a competitive advantage in an informed test market. The Australian government remains committed to the ecosystem that supports a thriving biotechnology sector. Let’s look at some of the best biotechnology companies that have strong future prospects are as follows:
Note: Market cap and share price are mentioned below as of 1 December 2023.
#1. Clinuvel Pharmaceuticals Limited (ASX: CUV)
Market capitalization: $833.55 million. (01, Dec 2023)
Sector/Industry: Healthcare/Biotechnology.
Current market price: $17.96.
Clinuvel Pharmaceuticals Limited (ASX: CUV) is a global specialty pharmaceutical group focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening acute disorders, as well as healthcare solutions for the general population.
The company has outlined a five-year projection of expenses excluding capital expenditures and marketing expenses on the Photo-Cosmetics initiative, worth $175 million, to the end of FY2025. Until now, FY2021–FY2023 total expenses incurred $92.8 million, or 53% of the expenses plan. The company exclusively performed with 29% growth in the cash balance generation of $156.81 million from the operations compared to its previous year of $121.51 million without reliance on debt or equity financing activities. It currently offers an attractive profitability ratio that is, an ROE of approximately 21%. Overall, development and performance signal a strong ability to provide a good value proposition to common shareholders.
#2. Telix Pharmaceuticals Limited (ASX: TLX)
Market capitalization: $3.22 billion. (01, Dec 2023)
Sector/Industry: Healthcare/Biotechnology.
Current market price: $9.945.
Telix Pharmaceuticals Limited (ASX: TLX) is a global, commercial-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using targeted radiation.
With its investigational imaging agents for brain and renal cancer, Telix has additional near-term commercial opportunities. The company is making progress with these two products with regulatory approvals, and a launch is planned for 2024. Telix has adopted AI at an early stage for more accurate diagnosis and personalised disease prediction. The company is investing in further growth opportunities.
#3. CSL Ltd. (ASX: CSL)
Market capitalization: 126.57 billion. (01, Dec 2023)
Sector/Industry: Healthcare/Biotechnology.
Current market price: $262.23.
CSL Limited (ASX: CSL) is a global biotechnology company that develops and delivers innovative medicines that save lives, protect public health, and help people with life-threatening medical conditions live full lives. Revenue saw growth of 31% on a constant currency basis in FY2023. The NPATA was $2.6 billion, up 20% at constant currency.
The company delivered its revenue growth projection to be in the range of approximately 9% to 11% on a constant currency basis over FY2023. The NPATA is expected to be in the range of approximately $2.9 billion to $3 billion at constant currency and growth of between 13% and 17%. The growth percentage does not take into account the one-off gain made from the sale proceeds of property in FY2023 of $44 million.
Frequently Asked Questions (F.A.Q)
What are the top 3 biotech stocks to buy?
Investment opportunities in the biotech sector range from discovery research to product development partnerships, and the advantages of doing business in Australia are many. There are several companies that are accountable for growth in the Australian biotech industry. Some of the three biotech stocks we expect to perform well down the line are Telix Pharmaceuticals Limited, CSL Limited, and Clinuvel Pharmaceuticals Limited.
Are biotech stocks a good investment?
A successful product launch by a biotech company may drive medical breakthroughs, which will lead to massive profit generation. However, these stocks are highly volatile due to factors like clinical trial outcomes and regulatory decisions, which present opportunities alongside risks.
What is the most profitable stock to buy right now?
ASX contains several fundamentally strong biotech companies that are constantly undergoing product trials and thriving to secure product approval. We have identified many, but one that can comment right now is CSL Limited. The revenue outcome presented a significant growth of 31% on a constant currency basis in FY2023. The NPATA was $2.6 billion, up 20% at constant currency. Additionally the company affirms its revenue growth projection to be in the range of approximately 9% to 11% on a constant currency basis over FY2023. Overall, the fundamentals are well tuned up to see a strong move going ahead.
Veye Pty Ltd(ABN 58 623 120 865), holds (AFSL No. 523157 ). All information provided by Veye Pty Ltd through its website, reports, and newsletters is general financial product advice only and should not be considered a personal recommendation to buy or sell any asset or security. Before acting on the advice, you should consider whether it’s appropriate to you, in light of your objectives, financial situation, or needs. You should look at the Product Disclosure Statement or other offer document associated with the security or product before making a decision on acquiring the security or product. You can refer to our Terms & Conditions and Financial Services Guide for more information. Any recommendation contained herein may not be suitable for all investors as it does not take into account your personal financial needs or investment objectives. Although Veye takes the utmost care to ensure accuracy of the content and that the information is gathered and processed from reliable resources, we strongly recommend that you seek professional advice from your financial advisor or stockbroker before making any investment decision based on any of our recommendations. All the information we share represents our views on the date of publishing as stocks are subject to real time changes and therefore may change without notice. Please remember that investments can go up and down and past performance is not necessarily indicative of future returns. We request our readers not to interpret our reports as direct recommendations. To the extent permitted by law, Veye Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss, or data corruption) (as mentioned on the website www.veye.com.au), and confirms that the employees and/or associates of Veye Pty Ltd do not hold positions in any of the financial products covered on the website on the date of publishing this report. Veye Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services.